Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis-Reference-Cited by-同舟云学术

Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis

Published:2019-03-13 Issue:7 Volume:35 Page:1297-1304
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Taxonera Carlos¹^ORCID,Iborra Marisa²,Bosca-Watts Marta Maia³,Rubio Saioa⁴,Nantes Óscar⁴,Higuera Rebeca⁵,Bertoletti Federico⁶,Martínez-Montiel Pilar⁷,Sierra-Ausin Mónica⁸,Manceñido Noemí⁹,Lázaro Pérez-Calle José¹⁰,Algaba Alicia¹¹,Olivares David¹^ORCID,Alba Cristina¹

Affiliation:

1. Department of Gastroenterology, Inflammatory Bowel Disease Unit, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, Spain;

2. Department of Gastroenterology and CIBERehd, Hospital Universitario La Fe, Valencia, Spain;

3. Department of Gastroenterology, Inflammatory Bowel Disease Unit, Hospital Clínico de Valencia, Valencia, Spain;

4. Department of Gastroenterology, Complejo Hospitalario de Navarra and Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain;

5. Department of Gastroenterology, Hospital Urduliz, Vizcaya, Spain;

6. Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;

7. Department of Gastroenterology, Hospital 12 de Octubre, Madrid, Spain;

8. Department of Gastroenterology, Hospital de León, León, Spain;

9. Department of Gastroenterology, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain;

10. Department of Gastroenterology, Hospital Universitario Fundación Alcorcón, Madrid, Spain;

11. Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Madrid, Spain

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2019.1579557

Reference28 articles.

1. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

2. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

3. US Food and Drug Administration. Simponi Summary of Product Characteristics [Internet] [cited 2018 May 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125289s024lbl.pdf

4. European Medicines Agency. Simponi Summary of Product Characteristics [Internet] [cited 2018 Nov 6]. Available from: https://ec.europa.eu/health/documents/community-register/2018/20180702141555/anx_141555_en.pdf

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review;Journal of Managed Care & Specialty Pharmacy;2024-09

2. The Efficacy of Currently Licensed Biologics for Treatment of Ulcerative Colitis: A Literature Review;Cureus;2023-04-15

3. Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?;Expert Opinion on Biological Therapy;2023-04-03

4. Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review;Advances in Therapy;2023-03-17

5. Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study;Alimentary Pharmacology & Therapeutics;2023-02-27